Safety and Effectiveness of Coronary Magnetic Resonance Angiography (CMRA) Imaging
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001633|
Recruitment Status : Completed
First Posted : December 10, 2002
Last Update Posted : March 4, 2008
Magnetic resonance imaging (MRI) is a diagnostic tool that creates high quality images of the human body without the use of X-ray (radiation). MRI is especially useful when studying the arteries of the heart (CMRA, coronary magnetic resonance angiography).
In this study researchers from several laboratories and hospitals will work together to determine the safety and effectiveness of CMRA with MS-325. MS-325 is a contrast agent. It is given to patients undergoing CRMA in order to improve the appearance of the arteries of the heart.
|Condition or disease||Intervention/treatment||Phase|
|Coronary Disease||Procedure: Coronary magnetic resonance angiography imaging||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Official Title:||A Phase II Feasibility Study of the Safety and Efficacy of Coronary Magnetic Resonance Angiography (CMRA) Imaging|
|Study Start Date :||September 1997|
|Estimated Study Completion Date :||December 2000|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001633
|United States, Maryland|
|National Heart, Lung and Blood Institute (NHLBI)|
|Bethesda, Maryland, United States, 20892|